Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30289956 | 1.00 | F12 (0.47) | F12F2 | |
| SCHEMBL5301574 | 0.91 | F12 (0.41) | F12 | |
| SCHEMBL6629846 | 0.84 | KCNH2 (0.50) | — | |
| SCHEMBL27544373 | 0.84 | F12 (0.44) | F12F2 | |
| Hydrochloric Acid SCHEMBL2258244 | 0.83 | KCNH2 (0.49) | — | |
| SCHEMBL10472776 | 0.81 | F12 (0.47) | F12F2 | |
| SCHEMBL19643872 | 0.81 | SLC6A2 (0.38) | F12 | |
| SCHEMBL768993 | 0.80 | F12 (0.42) | F12F2 | |
| SCHEMBL768982 | 0.80 | ALDH1A1 (0.54) | F12F2 | |
| SCHEMBL30899479 | 0.80 | ALDH1A1 (0.54) | F12F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630770-B1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-11603349-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD (AU) | 2023-03-14 | — | — | US | disclosed |
| US-11591336-B2 | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors | D. E. SHAW RESEARCH, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| CN-109475530-B | Aminoacyl indazole immunomodulators for treating autoimmune diseases | 洛克菲勒大学 | 2022-03-01 | — | — | CN | disclosed |
| US-20210246100-A1 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD (AU) | 2021-08-12 | — | — | US | disclosed |
| US-11014873-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD. (AU) | 2021-05-25 | — | — | US | disclosed |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
| EP-3630770-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | Relay Therapeutics, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-02-20 | — | — | US | disclosed |
| WO-2017123518-A1 | AMINOTRIAZOLE IMMUNOMODULATORS FOR TREATING AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017123518-A1 | AMINOTRIAZOLE IMMUNOMODULATORS FOR TREATING AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2017-07-20 | — | — | WO | disclosed |
| CN-103080104-B | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein | NOVARTIS AG | 2015-04-08 | — | — | CN | disclosed |
| US-8309734-B2 | Substituted pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2356094-A1 | NOVEL PHENYL AMIDE OR PYRIDIL AMIDE DERIVATIVES AND THEIR USE AS GPBAR1 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010049302-A1 | NOVEL PHENYL AMIDE OR PYRIDIL AMIDE DERIVATIVES AND THEIR USE AS GPBAR1 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105906-A1 | NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2010-04-29 | — | — | US | disclosed |
| US-5112836-A | Autoimmune diseases, antirheumatic agents and metabolic bone diseases | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1992-05-12 | — | — | US | disclosed |
| CN-1048216-A | Novel ring o-amino benzoyl acid carboxylic acid derivatives | SHU OGIHARA CO LTD (JP) | 1991-01-02 | — | — | CN | disclosed |
| EP-0403980-A1 | Novel cyclic anthranilic acid carboxylic acid derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1990-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603349-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, TGFB2 | F12 1476/4885F2 1087/4885 |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | PTPRJ, PTPN2, PTPN5 | F12 4555/4885F2 4738/4885 |
| US-20210246100-A1 | ANTI-FIBROTIC COMPOUNDS | TGFB1, SMAD3, TGFB2 | F12 1476/4885F2 1087/4885 |
| US-11014873-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, SMAD2 | F12 1499/4885F2 1217/4885 |
| US-11591336-B2 | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors | PTPN5, PTPN2, PTPN1 | F12 4405/4885F2 4731/4885 |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | TGFB1, SMAD3, SMAD2 | F12 603/4885F2 305/4885 |
| US-20100105906-A1 | NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES | GPBAR1, GPR119, GLP1R | F12 2023/4885F2 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.